Merck & Co., Inc. (MRK) stock
Close on Nov 12, 2026Market cap $362.55BP/E 151.5Yield 2.23%
Merck & Co., Inc. grew revenue 4.9% to $67.38B over the twelve months to Sep 30, 2026. Free cash flow was $14.75B, up 13.0% from a year earlier. At the latest close the market valued the company at $362.55B, 151.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $362.55B
- P/E ratio
- 151.5
- Price to sales
- 5.38
- Price to book
- 8.08
- Dividend yield
- 2.23%
- Free cash flow yield
- 4.07%
Fundamentals
- Revenue
- $67.38B
- Net income
- $2.45B
- EPS, diluted
- $0.97
- Free cash flow
- $14.75B
- Book value per share
- $18.12
- Diluted shares
- 2.48B
Trading
- Next earnings
- Feb 2, 2027 (estimated, before the open)
- Previous close
- $147.18
- Open
- $148.61
- Day's range
- $146.86 – $149.31
- Volume
- 6,108,079
- Average volume (20 days)
- 9,881,785
- Index membership
- S&P 500, Dow Jones Industrial Average, Russell 1000, Russell 3000
- Beta (5 years)
- 0.22
- 52-week range
- $90.90 – $156.92
- RSI (14 days)
- 51.2
- Volatility (1 year)
- 29.9%
- Relative volume
- 0.62×
- WACC
- 6.8%
On 1 of our idea list: Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, UDOW, DDM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MRK | S&P 500 | Difference | MRK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.0% | -2.7% | +3.7 pts | ||
| 3 months | +11.2% | -1.7% | +13.0 pts | ||
| Year to date | +42.5% | +11.9% | +30.6 pts | ||
| 1 year | +65.4% | +12.0% | +53.4 pts | ||
| 3 years | +58.8% | +78.2% | −19.4 pts | +16.7% | +21.2% |
| 5 years | +103.9% | +73.2% | +30.6 pts | +15.3% | +11.6% |
| 10 years | +226.8% | +309.6% | −82.8 pts | +12.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Merck filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Merck
Pharmaceutical Preparations
Merck & Co., Inc. is a global healthcare company that provides prescription medicines, biologic therapies, vaccines, and animal health solutions. Its business is managed across two operating segments: Pharmaceutical and Animal Health. The Pharmaceutical division supplies human therapeutics and vaccines across oncology, hospital acute care, cardiometabolic conditions, virology, and diabetes to drug wholesalers, retailers, hospitals, government agencies, and physicians. The Animal Health segment delivers veterinary medications, vaccines, and digital identification and monitoring technologies for livestock and companion animals to veterinarians, distributors, farmers, and pet owners.
Company profile, executives and historyMerck stock: common questions
What is Merck's stock price?
MRK closed at $146.95 on Nov 12, 2026, down 0.16% on the day. Over the past 52 weeks it traded between $90.90 and $156.92.
What is Merck's market cap?
Merck was worth $362.55B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MRK's P/E ratio?
MRK trades at 151.5 times earnings, based on diluted earnings per share of $0.97 over the twelve months to Sep 30, 2026.
How much revenue does Merck make?
Merck reported revenue of $67.38B for the twelve months to Sep 30, 2026, up 4.9% from a year earlier.
Does Merck pay a dividend?
Yes. Merck paid $3.28 per share over the last twelve months, a yield of 2.23% at the latest price, and has raised its annual dividend 15 years in a row.
When does Merck report earnings next?
Merck is expected to report Q4 FY2026 results on Feb 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MRK stock performed over the past year?
Including dividends, MRK returned +65.4% over the past year, against +12.0% for the S&P 500.
How many MRK shares are sold short?
27M shares were sold short at the latest FINRA report, 1.08% of the float, or 2.4 days of average trading volume.
Who are Merck's competitors?
Companies most similar to Merck by business, industry and size include PFE, LLY, GSK, ABBV, JNJ.
See a number that looks wrong?